溶瘤病毒
溶癌病毒
免疫疗法
癌症研究
癌症
免疫系统
肿瘤微环境
医学
免疫学
黑色素瘤
癌细胞
生物
内科学
作者
Simona Ruxandra Volovăț,Dragoş-Viorel Scripcariu,Ingrid-Andrada Vasilache,Cati Raluca Stolniceanu,Constantin Volovăț,Iolanda Augustin,Cristian Constantin Volovat,Madalina-Raluca Ostafe,Slevoacă-Grigore Andreea-Voichița,Toni Bejusca-Vieriu,Cristian Virgil Lungulescu,Daniel Sur,Diana Boboc
摘要
Oncolytic viruses (OVs) are emerging as potential treatment options for cancer. Natural and genetically engineered viruses exhibit various antitumor mechanisms. OVs act by direct cytolysis, the potentiation of the immune system through antigen release, and the activation of inflammatory responses or indirectly by interference with different types of elements in the tumor microenvironment, modification of energy metabolism in tumor cells, and antiangiogenic action. The action of OVs is pleiotropic, and they show varied interactions with the host and tumor cells. An important impediment in oncolytic virotherapy is the journey of the virus into the tumor cells and the possibility of its binding to different biological and nonbiological vectors. OVs have been demonstrated to eliminate cancer cells that are resistant to standard treatments in many clinical trials for various cancers (melanoma, lung, and hepatic); however, there are several elements of resistance to the action of viruses per se. Therefore, it is necessary to evaluate the combination of OVs with other standard treatment modalities, such as chemotherapy, immunotherapy, targeted therapies, and cellular therapies, to increase the response rate. This review provides a comprehensive update on OVs, their use in oncolytic virotherapy, and the future prospects of this therapy alongside the standard therapies currently used in cancer treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI